Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
Autor: | Jeremy Cetnar, Peter H. O'Donnell, Amir Mortazavi, T. Chen, Neal D. Shore, Emmett V. Schmidt, J. Burke, B. Bitman, Noah M. Hahn, C. Kresja, Mark D. Fleming, Leonard Joseph Appleman, Ajjai Alva, R. Izumi, Matthew I. Milowsky, A. Hamdy, Tian Zhang, Michael R. Harrison, Daniel J. George |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty Metastatic Urothelial Carcinoma CARCINOMA TRANSITIONAL CELL business.industry Hematology Pembrolizumab 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Platinum resistance medicine Acalabrutinib business 030217 neurology & neurosurgery |
Zdroj: | Annals of Oncology. 28:v303-v304 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |